Lynparza receives positive CHMP opinion for metastatic, castration-resistant prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval of Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login